Marc Lesnick

Marc Lesnick has a diverse work experience starting from 2003 to the present. Marc is currently working as the Sr. Vice President of Regulatory Affairs and Quality at Peptilogics since June 2021. Prior to that, they served as the Chief Development Officer and Board Member at Park Therapeutics, Inc. from January 2020 to May 2021. From June 2019 to November 2020, they held the position of Vice President of Regulatory Affairs and Quality at Spruce Biosciences. Before that, Marc Lesnick worked as the Sr. VP of Regulatory Affairs at QED Therapeutics from April 2018 to April 2019, and as the Sr. VP of Regulatory Affairs and Quality at Cascadian Therapeutics, Inc. from January 2017 to March 2018. Marc also served as the Sr. Vice President of US Regulatory Affairs - Global Development Projects at Shionogi Inc. from May 2013 to December 2016. In their earlier career, Marc Lesnick held positions such as Vice President of Regulatory Affairs and Director of Regulatory Affairs at Optimer Pharmaceuticals, Manager of Regulatory Affairs at Verus Pharmaceuticals, and Consultant of Regulatory Affairs at PAREXEL. Marc began their career as a Scientific Review Administrator at NIAID/NIH.

Marc Lesnick completed their Bachelor of Arts degree in Biochemistry from the University of California, Santa Cruz in 1991. Marc then pursued a Ph.D. in Molecular Biology from the University of Oregon, where they studied from 1991 to 1997.